Blockade of LTB4/BLT1 pathway improves CD8+ T‐cell‐mediated colitis

• Published in: Inflammatory bowel diseases Vol. 17; no. 1; pp. 279 - 288
• Main Authors: Nancey, Stephane, Boschetti, Gilles, Hacini, Feriel, Sardi, Fatima, Durand, Pierre‐Yves, Le Borgne, Maylis, Furhmann, Lydie, Flourie, Bernard, Kaiserlian, Dominique
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.01.2011
• Subjects: BLT1 antagonists; Body weight loss; CD8 antigen; CD8+ T cells; Colitis; Colon; Cytotoxicity; Data processing; Dendritic cells; endopeptidase; Enzyme-linked immunosorbent assay; Immunization; Inflammation; Inflammatory bowel diseases; Interferon; Intestine; Leukotriene B4; LTB4; Lymph nodes; Lymphocytes T; Lymphoid cells; Receptor mechanisms; Serine proteinase; T-cell receptor

Background: Leukotriene B4 (LTB4) has chemotactic properties for activated T cells expressing the high‐affinity receptor BLT1. This study investigated whether the LTB4 antagonist (CP‐105,693), selective for BLT1 receptor, could protect mice from colitis mediated by specific cytotoxic CD8+ T lymphocy...